~~<i id='ABA23C9E11'><strike id='ABA23C9E11'><tt id='ABA23C9E11'><pre id='ABA23C9E11'></pre></tt></strike></i>~~

Home» focus» comprehensive

comprehensive

author：comprehensive 2025-10-02 14:29:08 Page View：2651

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Beach reads and more: STAT's 2023 summer book list
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

comprehensive

Guidelines to prevent youth baseball injuries need more muscle

Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

8:14FormerU.S.PresidentDonaldTrumpisdisplayedonascreenduringameetingoftheSelectCommitteetoInvestigat

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later

0:45OfficerNickolasWilt,a26-year-oldrookiewhowasshotinthehead,willbedischargedonJuly28,2023,aftermor

WSS

comprehensive

comprehensive

explore

comprehensive

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later